Loading clinical trials...

Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil (150, 200, and 250 mg) and PROVIGIL® (200 mg) in Patients With Chronic Shift Work Sleep Disorder

NCT00236080•Cephalon

View on ClinicalTrials.gov

Summary

The purpose of the study is to compare the overnight efficacy and plasma concentration-time profiles of armodafinil and PROVIGIL, after multiple doses, in patients with excessive sleepiness associated with chronic Shift Work Sleep Disorder (SWSD).

Detailed Description

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL in Patients with Chronic Shift Work Sleep Disorder

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients are included in the study if all of the following criteria are met:
•The patient speaks and writes in English.
•The patient is a man or woman of any ethnic origin aged 18 through 65 years.
•The patient is in good health as determined by a medical and psychiatric history, medical examination, serum chemistry, and hematology.
•The patient has a diagnosis of SWSD according to the International Classification of Sleep Disorders (ICSD) criteria, and must have had excessive sleepiness during night shifts for at least 3 months.
•The patient must be planning to work at least 3 to 5 nights (per week), of which at least 3 nights will be consecutive.
•The patient must work night shifts that include at least 6 hours between 2200 and 0800 (+30 minutes) and be no longer than 12 hours (+30 minutes) in duration.
•The patient has a mean sleep latency of 6 minutes or less as determined by the MSLT (average of naps at 0100, 0300, 0500, and 0700).
•The patient has a Clinical Global Impression of Severity of Illness (CGI-S) rating of 4 or more as it pertains to sleepiness during night shifts including the commute from work.
•Women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, steroidal contraceptive (oral, transdermal, implanted and injected) in conjunction with a barrier method, and intrauterine device (IUD).
+2 more criteria

Exclusion Criteria

•Patients are excluded from participating in this study if 1 or more of the following criteria are met:
•The patient has any clinically significant medical or psychiatric conditions (treated or untreated).
•The patient has a probable diagnosis of a current sleep disorder other than SWSD.
•The patient consumes caffeine including coffee, tea, and/or other caffeine-containing beverages or foods averaging more than 600 mg of caffeine/day within 2 weeks of the start of study drug administration.
•The patient has medically unexplainable positive urine drug screen (UDS) result at the screening visit.
•The patient has clinically significant deviation from normal in clinical laboratory results, vital signs, or physical examination.
•The patient has received any investigational drug within 30 days or 5 half-lives (whichever is longer) before study drug administration, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before study drug adminstration.
•The patient used any prescription drugs disallowed by the protocol or clinical significant use of over-the-counter (OTC) drugs within 7 days before the second screening/baseline visit.
•The patient has any disorder (including gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion.
•The patient has known or suspected hypersensitivity to stimulants and/or modafinil or any ingredient present in the study drug.
+3 more criteria

Locations (20)

Psypharma Clinical Research

Phoenix, Arizona, United States

PsyPharma Clinical Tucson

Tucson, Arizona, United States

Central Arkansas Research

Hot Springs, Arkansas, United States

Pacific Sleep Medicine Service

Los Angeles, California, United States

Pacific Sleep Medicine Service

San Diego, California, United States

BMR HealthQuest

San Diego, California, United States

Stanford University

Stanford, California, United States

Neurotrials Research

Atlanta, Georgia, United States

SLEEPMED, Inc.

Macon, Georgia, United States

Henry Lahmeyer, MD

Northfield, Illinois, United States

Key Dates

Start Date

August 1, 2005

Completion Date

December 1, 2005

Last Updated

July 19, 2013

Enrollment

136

ACTUAL participants

Conditions

Chronic Shift Work Sleep Disorder

Interventions

PROVIGIL 200 mg

DRUG

Armodafinil 250 mg

DRUG

Armodafinil 200 mg

DRUG

Armodafinil 150 mg

DRUG

Placebo

DRUG